Expert Opinion on Therapeutic Targets最新文献_第7页

Targeting GABA receptors with chalcone derivative compounds, what is the evidence? 用查尔酮衍生物化合物靶向 GABA 受体，证据何在？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-19 DOI: 10.1080/14728222.2023.2293752

Feba Benny, Sunil Kumar, Aiswarya Binu, Della Grace Thomas Parambi, Tariq G. Alsahli, Abdullah G. Al-Sehemi, Namitha Chandran, Deepthi S. Manisha, Sarath Sreekumar, Akanksha Bhatt, Krishnadas Madhu, Bijo Mathew

引用次数: 0

Novel signatures of prostate cancer progression and therapeutic resistance 前列腺癌进展和耐药性的新特征

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-18 DOI: 10.1080/14728222.2023.2293757

Jason Wang, Reuben Ben-David, Reza Mehrazin, Wei Yang, Ashutosh K. Tewari, Natasha Kyprianou

引用次数: 0

How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy? 肿瘤学基因靶点的识别和治疗干预在未来治疗中将如何发展？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-14 DOI: 10.1080/14728222.2023.2295493

Paolo Baldo, Valli De Re, Mattia Garutti

引用次数: 0

XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma XBP1 作为减轻肝细胞癌耐药性的新型分子靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-11 DOI: 10.1080/14728222.2023.2293746

Zahra Hendi, Pedram Asadi Sarabi, David Hay, Massoud Vosough

引用次数: 0

Advances in targeting the extracellular matrix for glaucoma therapy: current updates 针对细胞外基质治疗青光眼的进展：最新进展

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-09 DOI: 10.1080/14728222.2023.2293748

R. Agarwal, I. Iezhitsa

引用次数: 0

Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening 通过多重基因组编辑 CRISPR 筛选揭示急性髓性白血病的治疗靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-09 DOI: 10.1080/14728222.2023.2293751

Zhen Tian, Stacia Octaviani, Jian Huang

引用次数: 0

Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy 解码胃腺癌中 MUC3A 的表达模式：揭示成功免疫疗法的关键所在

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-08 DOI: 10.1080/14728222.2023.2293764

Masoud Sotoudeh, Vahid Mansouri, Ramin Shakeri, Bahareh Sharififard, Nasim Sajadi, Vahid Haghpanah, Mahmood Naderi

引用次数: 0

Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap. 探索卵巢癌症的肿瘤免疫微环境：通往治疗路线图的途径。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-09-15 DOI: 10.1080/14728222.2023.2259096

Basharat Ahmad Bhat, Ifra Saifi, Nizar A Khamjan, Syed Suhail Hamdani, Abdullah Algaissi, Safeena Rashid, Mohammed M Alshehri, Showkat Ahmad Ganie, Mohtashim Lohani, Siddig Ibrahim Abdelwahab, Sajad Ahmad Dar

{"title":"Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap.","authors":"Basharat Ahmad Bhat, Ifra Saifi, Nizar A Khamjan, Syed Suhail Hamdani, Abdullah Algaissi, Safeena Rashid, Mohammed M Alshehri, Showkat Ahmad Ganie, Mohtashim Lohani, Siddig Ibrahim Abdelwahab, Sajad Ahmad Dar","doi":"10.1080/14728222.2023.2259096","DOIUrl":"10.1080/14728222.2023.2259096","url":null,"abstract":"Introduction: Despite cancer treatment strides, mortality due to ovarian cancer remains high globally. While immunotherapy has proven effective in treating cancers with low cure rates, it has limitations. Growing evidence suggests that both tumoral and non-tumoral components of the tumor immune microenvironment (TIME) play a significant role in cancer growth. Therefore, developing novel and focused therapy for ovarian cancer is critical. Studies indicate that TIME is involved in developing ovarian cancer, particularly genome-, transcriptome-, and proteome-wide studies. As a result, TIME may present a prospective therapeutic target for ovarian cancer patients.Areas covered: We examined several TIME-targeting medicines and the connection between TIME and ovarian cancer. The key protagonists and events in the TIME and therapeutic strategies that explicitly target these events in ovarian cancer are discussed.Expert opinion: We highlighted various targeted therapies against TIME in ovarian cancer, including anti-angiogenesis therapies and immune checkpoint inhibitors. While these therapies are in their infancy, they have shown promise in controlling ovarian cancer progression. The use of 'omics' technology is helping in better understanding of TIME in ovarian cancer and potentially identifying new therapeutic targets. TIME-targeted strategies could account for an additional treatment strategy when treating ovarian cancer.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10358825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of novel antimicrobial carbonic anhydrase inhibitors. 新型抗微生物碳酸酐酶抑制剂综述。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-10-30 DOI: 10.1080/14728222.2023.2263914

Claudiu T Supuran

{"title":"An overview of novel antimicrobial carbonic anhydrase inhibitors.","authors":"Claudiu T Supuran","doi":"10.1080/14728222.2023.2263914","DOIUrl":"10.1080/14728222.2023.2263914","url":null,"abstract":"Introduction: Four different genetic families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) are present in bacteria, α-, β-, γ- and ι-CAs. They play relevant functions related to CO2, HCO3-/H+ ions homeostasis, being involved in metabolic biosynthetic pathways, pH regulation, and represent virulence and survival factors for bacteria in various niches. Bacterial CAs started to be considered druggable targets in the last decade, as their inhibition impairs survival, growth, and virulence of these pathogens.Areas covered: Significant advances were registered in the last years for designing effective inhibitors of sulfonamide type for Helicobacter pylori α-CA, Neisseria gonorrhoeae α-CA, vacomycin-resistant enterococci (VRE) α- and γ-CAs, for which the in vivo validation has also been achieved. MIC-s in the range of 0.25-4.0 µg/mL for wild type and drug resistant N. gonorrhoeae strains, and of 0.007-2.0 µg/mL for VRE were observed for some 1,3,4-thiadiazole-2-sulfonamides, and acetazolamide was effective in gut decolonization from VRE.Expert opinion: Targeting bacterial CAs from other pathogens, among which Vibrio cholerae, Mycobacterium tuberculosis, Brucella suis, Salmonella enterica serovar Typhimurium, Legionella pneumophila, Porphyromonas gingivalis, Clostridium perfringens, Streptococcus mutans, Burkholderia pseudomallei, Francisella tularensis, Escherichia coli, Mammaliicoccus (Staphylococcus) sciuri, Pseudomonas aeruginosa, may lead to novel antibacterials devoid of drug resistance problems.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":5.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update. 靶向背根神经节和初级感觉神经元治疗慢性疼痛：最新进展。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-08-22 DOI: 10.1080/14728222.2023.2247563

Temugin Berta, Judith A Strong, Jun-Ming Zhang, Ru-Rong Ji

{"title":"Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update.","authors":"Temugin Berta, Judith A Strong, Jun-Ming Zhang, Ru-Rong Ji","doi":"10.1080/14728222.2023.2247563","DOIUrl":"10.1080/14728222.2023.2247563","url":null,"abstract":"Introduction: Current treatments for chronic pain are inadequate. Here, we provide an update on the new therapeutic strategies that target dorsal root ganglia (DRGs) in the peripheral nervous system for a better and safer treatment of chronic pain.Areas covered: Despite the complex nature of chronic pain and its underlying mechanisms, we do know that changes in the plasticity and modality of neurons in DRGs play a pivotal role. DRG neurons are heterogenous and offer potential pain targets for different therapeutic interventions. We discuss the last advancements of these interventions, which include the use of systemic and local administrations, selective nerve drug delivery, and gene therapy. In particular, we provide updates and further details on the molecular characterization of primary sensory neurons, new analgesics entering the market, and future gene therapy approaches.Expert opinion: DRGs and primary sensory neurons are promising targets for chronic pain treatment due to their key role in pain signaling, unique anatomical location, and the potential for different targeted therapeutic interventions.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0